news

2026-07-20

Risen Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease

Year:

2023-02-03

First in China: ANGPTL3 siRNA drug developed Risen and TopAlliance jointly approved for clinical trial.

2022-11-22

Congratulations! Risen successfully acquired the identification as the national high-tech enterprise!

2021-10-19

Risen signed a strategic cooperation agreement with China Merchants Bank Shanghai Branch

Shanghai Zhangjiang R&D Center.

Suzhou Industrial Park R&D Center.

Jiangsu Xuzhou R&D Center